Patient-Reported Outcomes from IMfirst: Chemotherapy Plus Atezolizumab in a Real-World Setting of Extensive-Stage SCLC

Chest pain, dyspnea, and cough are the lung cancer-related symptoms most frequently reported in patients with extensive-stage small cell lung cancer (ES-SCLC), with a negative clinical impact on health-related quality of life (HRQoL). IMpower133 showed that adding atezolizumab (ATZ) to platinum-etoposide as first-line treatment for ES-SCLC improved overall survival and progression-free survival compared to platinum-etoposide alone, and the combination had no additional negative impact on patient-reported lung cancer-related symptoms, physical function, or HRQoL.